Viva Biotech Holdings Past Earnings Performance
Past criteria checks 0/6
Viva Biotech Holdingshan disminuido a un ritmo medio anual de -35.3%, mientras que en la industria Life Sciences los ingresos han sido de growing a 27.8% anuales. Los ingresos han sido growing a una tasa media anual de 43.5%.
Key information
-32.4%
Earnings growth rate
-32.6%
EPS growth rate
| Life Sciences Industry Growth | 41.4% |
| Revenue growth rate | 41.6% |
| Return on equity | -2.7% |
| Net Margin | -5.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump
Jan 19
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 01These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way
Sep 25Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?
Jul 11These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively
Apr 14Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?
Dec 23Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?
Nov 06Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Jun 13We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt
Apr 17Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain
Mar 13Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares
Feb 06What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?
Jan 02Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?
Nov 21
Revenue & Expenses BreakdownBeta
How Viva Biotech Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,156 | -116 | 418 | 128 |
| 30 Sep 23 | 2,284 | -276 | 417 | 150 |
| 30 Jun 23 | 2,413 | -436 | 416 | 172 |
| 31 Mar 23 | 2,396 | -482 | 413 | 154 |
| 31 Dec 22 | 2,380 | -528 | 410 | 136 |
| 30 Sep 22 | 2,283 | -209 | 398 | 116 |
| 30 Jun 22 | 2,186 | 111 | 385 | 96 |
| 31 Mar 22 | 2,145 | 199 | 353 | 94 |
| 31 Dec 21 | 2,104 | 288 | 322 | 92 |
| 30 Sep 21 | 1,815 | 258 | 271 | 87 |
| 30 Jun 21 | 1,526 | 228 | 219 | 81 |
| 31 Mar 21 | 1,111 | -79 | 171 | 74 |
| 31 Dec 20 | 697 | -387 | 123 | 66 |
| 30 Sep 20 | 538 | -349 | 96 | 59 |
| 30 Jun 20 | 378 | -311 | 70 | 52 |
| 31 Mar 20 | 351 | -23 | 62 | 48 |
| 31 Dec 19 | 323 | 266 | 55 | 45 |
| 30 Sep 19 | 299 | 176 | 48 | 37 |
| 30 Jun 19 | 275 | 86 | 42 | 30 |
| 31 Mar 19 | 243 | 88 | 36 | 27 |
| 31 Dec 18 | 210 | 91 | 30 | 25 |
| 31 Dec 17 | 148 | 76 | 17 | 17 |
| 31 Dec 16 | 96 | 24 | 14 | 17 |
Beneficios de calidad: 1873 actualmente no es rentable.
Creciente margen de beneficios: 1873 actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: 1873 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 35.3% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 1873 en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: 1873 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Life Sciences (-2.2%).
Return on Equity
Alto ROE: 1873 tiene un Rendimiento de los fondos propios negativo (-11.13%), ya que actualmente no es rentable.